List of Excipients in Branded Drug MEXILETINE HYDROCHLORIDE

Generic Drugs Containing MEXILETINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	ALCOHOL
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	AMMONIA
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	BUTYL ALCOHOL
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	D&C RED NO. 28
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	mexiletine hydrochloride	0093-8739	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in MEXILETINE HYDROCHLORIDE?

# Of NDCs	Excipient
20	ALCOHOL
36	AMMONIA
20	BUTYL ALCOHOL
13	D&C RED NO. 28
11	D&C YELLOW NO. 10
24	FD&C BLUE NO. 1
5	FD&C BLUE NO. 2

# Mexiletine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Mexiletine hydrochloride is a mature, immediate-release antiarrhythmic with limited basic-molecule patent protection and established generic competition. The strongest commercial opportunities are differentiated formulations, improved gastrointestinal tolerability, flexible dosing, pediatric or dysphagia-friendly products, and specialty indications such as myotonia and sodium-channel disorders. Excipient selection should prioritize rapid and reproducible dissolution, capsule stability, dose uniformity, and mitigation of nausea, dyspepsia and other dose-limiting effects.

What is the commercial status of mexiletine hydrochloride?

Mexiletine hydrochloride is an orally active class IB sodium-channel blocker. The reference product, Mexitil, was approved in the United States for documented ventricular arrhythmias that are life-threatening. Current U.S. products are primarily generic capsules in 150 mg, 200 mg and 250 mg strengths, although availability can vary by manufacturer and supply channel.[1][2]

Attribute	Commercial assessment
Active ingredient	Mexiletine hydrochloride
Dosage form	Immediate-release oral capsules
Reference product	Mexitil
Main approved use	Life-threatening ventricular arrhythmias
Common specialty uses	Myotonia, nondystrophic myotonia, sodium-channel disorders, neuropathic pain research
Patent position	Legacy small molecule; basic compound exclusivity is expired
Current exclusivity	No meaningful new-molecular-entity exclusivity
Generic competition	Established
Primary formulation risk	Gastrointestinal intolerance and variable patient adherence
Highest-value product opportunity	Better-tolerated oral delivery with equivalent systemic exposure

Mexiletine is commercially relevant in small but defensible specialty markets. Demand is concentrated among cardiology, electrophysiology, neurology and rare-disease prescribers. The product is not a high-volume primary-care medicine, which limits the value of undifferentiated generic capsules.

What patents protect mexiletine hydrochloride products?

The original composition-of-matter protection for mexiletine hydrochloride has expired. A new entrant should not expect to obtain meaningful exclusivity from the active pharmaceutical ingredient alone.

The remaining intellectual-property opportunities are more likely to involve:

• Modified-release dosage forms
• Multiparticulate or sprinkle formulations
• Taste-masked liquid products
• Low-irritancy or gastroprotective formulations
• Specific excipient combinations
• New dosing regimens
• Treatment of non-cardiac channelopathies
• Manufacturing processes that improve purity, yield or impurity control
• Device-assisted delivery systems

An Orange Book review should be performed at the product level before launch. The absence of an active composition patent does not eliminate the possibility of listed formulation or method-of-use patents associated with a particular sponsor’s product.[3]

What is the Orange Book status of mexiletine hydrochloride?

Mexiletine hydrochloride is generally treated as a legacy generic product rather than a product with current reference-product exclusivity. FDA Orange Book analysis should distinguish among:

1. The original reference product.
2. Approved abbreviated new drug applications.
3. Any later branded or authorized-generic products.
4. Listed patents tied to a specific NDA.
5. Patent certifications and litigation associated with a proposed ANDA.

Because the commercial market consists largely of established generic capsules, a new product would usually compete through an ANDA if it remains pharmaceutically equivalent to the reference product. A materially different delivery system may require a 505(b)(2) pathway, especially if it changes release characteristics, dosing frequency, administration route or patient population.[4]

When does mexiletine hydrochloride lose exclusivity?

Mexiletine hydrochloride lost practical small-molecule exclusivity many years ago. The opportunity is therefore not a conventional loss-of-exclusivity launch based on an imminent patent cliff. It is a reformulation and specialty-market opportunity.

Exclusivity category	Position
Composition-of-matter patent	Expired
New chemical entity exclusivity	Expired
Conventional capsule generic entry	Established
Orphan-drug exclusivity for original cardiac indication	Not a current commercial barrier
Formulation exclusivity	Product-specific and potentially available
Method-of-use exclusivity	Potentially available for new indications, subject to FDA approval
Pediatric exclusivity	No general current barrier should be assumed
Regulatory exclusivity for a new product	Depends on pathway and approval basis

A new formulation could obtain patent protection even though the active ingredient is old. The commercial value of that protection depends on whether the formulation produces a measurable clinical benefit and whether the claims survive obviousness, enablement and written-description challenges.

Which excipients are suitable for mexiletine hydrochloride capsules?

Mexiletine hydrochloride is a basic, water-soluble salt with a clinically important exposure profile. An immediate-release formulation should avoid unnecessary release retardation and should deliver consistent dissolution across physiologic pH conditions.

Core excipient strategy

Formulation function	Candidate excipients	Strategic purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Fill weight, compactability and dose uniformity
Binder	Povidone, pregelatinized starch, low-substituted hydroxypropyl cellulose	Granule strength and content uniformity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid capsule-content dispersion
Glidant	Colloidal silicon dioxide	Powder flow and capsule-fill consistency
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and manufacturing robustness
Wetting agent	Polysorbate 80 or sodium lauryl sulfate, where justified	Improved wetting of hydrophobic excipient matrices
Capsule shell	Gelatin or hypromellose	Shell compatibility and patient preference
Taste masking	Polymer coating, ion-exchange resin, lipid barrier	Liquid, sprinkle or orally dispersible products
Release modifier	Hypromellose, ethylcellulose, methacrylate copolymers	Sustained or delayed release

The default commercial formulation should use a conventional filler-disintegrant-lubricant system. A simple formulation reduces excipient-related regulatory risk and makes comparative dissolution easier. Over-engineering an immediate-release capsule could create a bioequivalence problem without producing a clinical advantage.

Which excipients can improve gastrointestinal tolerability?

Mexiletine is associated with nausea, heartburn, dyspepsia and other gastrointestinal adverse effects. The label recommends administration with food or an antacid when necessary, which creates a formulation opportunity but also raises a critical development issue: the product must preserve exposure under fed and fasting conditions consistent with its intended labeling.[1]

Potential approaches include:

• Lower peak concentration through controlled release
• Multiparticulate delivery to distribute drug release
• Polymer or lipid matrices that reduce local gastric concentration
• Delayed release to reduce gastric exposure
• Co-administration-compatible formulation designs
• Smaller unit doses with more flexible titration

A gastro-resistant formulation may reduce gastric exposure, but it can also alter absorption timing and total exposure. It should not be pursued solely on the basis of an excipient rationale. Comparative pharmacokinetic studies, food-effect studies and clinical tolerability data would be required.

What formulations are protected by the strongest commercial strategy?

Immediate-release capsules

This is the lowest-risk entry strategy and the most direct substitute for established generics. The main advantages are:

• Familiar dosage form
• Straightforward ANDA positioning
• Established dosing strengths
• Low manufacturing complexity
• Broad pharmacy substitution potential

The disadvantages are price pressure, limited differentiation and direct competition with existing suppliers.

Modified-release capsules or tablets

A once-daily or twice-daily formulation could improve adherence and reduce peak-related adverse effects. The development burden is materially higher because the sponsor must establish:

• Equivalent or clinically appropriate exposure
• Dose proportionality
• Food-effect behavior
• Steady-state pharmacokinetics
• Safe conversion from immediate-release treatment
• Adequate control of dose dumping

Modified release has the highest potential for patent differentiation but also the greatest clinical and regulatory risk.

Sprinkle or multiparticulate capsules

A capsule that can be opened and sprinkled on soft food could address dysphagia, neuromuscular disease and some pediatric-use scenarios. This strategy is relevant because patients treated for myotonia or rare sodium-channel disorders may have swallowing or administration challenges.

Key excipient requirements include:

• Rapid release after administration
• Low particle segregation
• Acceptable taste and mouthfeel
• Stability after capsule opening
• Demonstrated compatibility with permitted soft foods
• Low risk of dose loss during transfer

A multiparticulate system could also support a controlled-release claim while preserving capsule-based administration.

Oral liquid

An oral solution or suspension could target pediatric, geriatric and dysphagia populations. The main technical risks are taste, chemical stability, microbial control and dose-measurement accuracy.

A liquid product may require:

• Buffer control
• Preservative selection
• Solubilizer or cosolvent optimization
• Taste masking
• Container-closure protection
• A calibrated oral syringe
• In-use stability data

A true solution may provide better dose uniformity than a suspension, but high drug loading and palatability can be difficult. Ion-pairing, resin complexation or polymeric taste masking could support a differentiated product.

How strong is the mexiletine hydrochloride patent estate?

The patent estate is weak for the active ingredient and potentially moderate for a well-supported reformulation. Patent strength depends on claim scope and clinical evidence rather than the age of the molecule.

IP category	Relative strength	Commercial value
Mexiletine composition of matter	Low, expired	Minimal
Conventional capsule composition	Low to moderate	Limited unless manufacturing cost is superior
Modified-release formulation	Moderate	High if adherence or tolerability improves
Sprinkle formulation	Moderate	Niche but defensible
Oral liquid and taste masking	Moderate	Useful for specialty populations
New method of treatment	Moderate to high	Depends on indication and clinical data
Manufacturing process	Moderate	Protects supply reliability and impurity control
Device or packaging system	Low to moderate	Supports product differentiation

A strong formulation patent should claim measurable relationships among particle size, release profile, excipient ratios, dissolution performance and pharmacokinetic outcomes. Broad claims that merely list common excipients are vulnerable to obviousness attacks.

What generic entry risks exist for a new mexiletine product?

Paragraph IV challenges

A conventional generic capsule could face Paragraph IV certification if an Orange Book-listed patent covers the reference product. For a legacy product, the more likely risk is not a basic-molecule patent but a later-listed formulation or use patent.

A reformulated product may face a different risk profile:

• An ANDA may be blocked by listed patents tied to the reference product.
• A 505(b)(2) product may face patent certification requirements.
• A formulation patent can be challenged by generic sponsors after commercial success.
• Method-of-use claims may be carved out through a section viii statement where legally and operationally feasible.

FDA approval, patent certification and commercial launch timing must be analyzed separately. Regulatory approval does not by itself eliminate patent-based injunction risk.[4][5]

Biosimilar risk

Biosimilar competition is not relevant. Mexiletine hydrochloride is a synthetic small molecule, not a biologic. Competition will arise from ANDA generics, authorized generics, specialty manufacturers and reformulated products.

What FDA regulatory pathway is most suitable?

Product concept	Likely pathway	Development burden
Conventional immediate-release capsule	ANDA	Low to moderate
Same capsule with new inactive ingredients	ANDA if bioequivalent and otherwise eligible	Moderate
New oral liquid equivalent to capsule	505(b)(2) or ANDA, depending on product design	Moderate
Modified-release product	505(b)(2) or product-specific ANDA pathway	High
New indication	505(b)(2) or supplemental NDA	High
Pediatric or rare-disease formulation	505(b)(2), with indication-specific evidence	Moderate to high

The most efficient development sequence is usually an immediate-release generic for supply entry, followed by a specialty formulation supported by clinical differentiation. A sponsor should avoid building the business case around price alone because established capsule products can compress margins quickly.

What commercial opportunities exist for excipient suppliers and manufacturers?

Excipient suppliers

Excipient companies can create value through:

• Taste-masking platforms for oral liquid mexiletine
• Controlled-release polymers for lower peak exposure
• Direct-compression systems that improve content uniformity
• Low-nitrite or low-peroxide excipients where impurity control is relevant
• Capsule-shell systems with improved moisture protection
• Multiparticulate coating technologies
• Excipient packages qualified for pediatric and dysphagia-friendly products

The most attractive opportunity is a platform that can be linked to clinical outcomes, such as reduced peak-related intolerance or improved adherence.

Finished-dose manufacturers

Manufacturers can compete through:

• Reliable supply of all three conventional strengths
• Contract manufacturing for specialty pharmacies
• Small-batch production for rare neuromuscular indications
• Oral liquids and sprinkle capsules
• Integrated packaging with oral syringes
• Direct-to-specialty-pharmacy distribution
• Geographic expansion outside the United States

Supply reliability has practical value because mexiletine is used by patients who may have limited therapeutic alternatives. Manufacturing controls should focus on assay uniformity, dissolution, capsule-fill weight, degradation products and stability under elevated temperature and humidity.

How does mexiletine compare with competing antiarrhythmic products?

Product	Main commercial use	Formulation opportunity	Competitive constraint
Mexiletine	Ventricular arrhythmias; specialty neurologic uses	Modified release, liquid, sprinkle	GI intolerance and niche market
Lidocaine	Acute ventricular arrhythmia treatment	Injectable delivery	Hospital-only or acute-use positioning
Amiodarone	Broad arrhythmia management	Oral and injectable products	Toxicity and extensive monitoring
Flecainide	Supraventricular and ventricular arrhythmias	Conventional oral products	Different clinical positioning
Ranolazine	Antianginal therapy; some electrophysiology use	Extended release	Not a direct substitute for all indications

Mexiletine’s commercial advantage is its established role in patients who require oral sodium-channel blockade. Its weakness is the limited volume of patients and the tolerability burden. A product that improves administration or tolerability can compete without displacing every established antiarrhythmic.

What licensing deals could support a mexiletine product?

Licensing opportunities are most credible in four areas:

1. Controlled-release polymer technology.
2. Taste-masking and pediatric liquid technology.
3. Multiparticulate capsule systems.
4. Specialty commercialization through neurology and rare-disease channels.

A license should be evaluated against the absence of basic-molecule exclusivity. High upfront payments are difficult to justify unless the technology creates a clearly differentiated product, supports patent claims and improves reimbursement or adherence.

Key Takeaways

• Mexiletine hydrochloride is a mature generic small molecule with expired basic patent protection.
• Conventional immediate-release capsules are the lowest-risk entry but offer limited pricing power.
• Modified release, sprinkle capsules and oral liquids provide the strongest formulation opportunities.
• Excipient selection should focus on dissolution consistency, GI tolerability, taste masking and dose flexibility.
• Biosimilar competition is irrelevant; ANDA generics and 505(b)(2) reformulations are the principal competitive threats.
• The strongest patent strategy links excipient composition to measurable release, pharmacokinetic or tolerability advantages.
• Commercial success will depend more on specialty distribution, reliable supply and patient usability than on commodity capsule pricing.

FAQs

Can mexiletine hydrochloride be developed as a pediatric oral liquid?

Yes. A pediatric liquid could address swallowing limitations and weight-based dosing, but taste masking, chemical stability, preservative performance and dosing-device accuracy are central development requirements.

Is a once-daily mexiletine product commercially attractive?

Potentially. A once-daily product could improve adherence and reduce peak-related intolerance, but it would require substantial pharmacokinetic, food-effect and dose-conversion evidence.

Which excipient is best for mexiletine hydrochloride?

No single excipient is universally optimal. A conventional immediate-release capsule would typically use a filler, disintegrant, glidant and lubricant selected to achieve rapid dissolution and reliable content uniformity.

Can a mexiletine formulation obtain new patent protection?

Yes. A formulation, delivery system, manufacturing method or approved method of treatment may be patentable even though the active ingredient is old. The claims must provide a non-obvious and technically supported advantage.

Is mexiletine hydrochloride suitable for a 505(b)(2) product?

Yes, particularly for a modified-release dosage form, oral liquid, sprinkle product, new administration method or new indication. The regulatory strategy depends on the extent of clinical and pharmacokinetic differences from the reference product.

References

1. U.S. Food and Drug Administration. (2023). Mexitil (mexiletine hydrochloride) prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). Mexiletine hydrochloride drug information and product labeling. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and patent certifications. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. Center for Drug Evaluation and Research.